Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970489 · ClinicalTrials.gov registry record · Phase 3
Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,516
- Enrollment target
- 1
- Study location
NCT00970489: Completed Phase 3 study of Atrial Fibrillation, sponsored by Brigham and Women's Hospital.
NCT00970489 is a Phase 3 study of Atrial Fibrillation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,516 participants, below the 2,989-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00970489, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,516 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a large multi-center study to examine whether peri-operative intake of n-3 polyunsaturated fatty acids (PUFA) will reduce the occurrence of post-operative atrial fibrillation or flutter (AF) in patients undergoing cardiac surgery (CS).
Primary Outcome
Primary: Occurrence of post-CS AF (atrial fibrillation or flutter) of at least 30 seconds duration and confirmed by rhythm strip or 12-lead ECG. This will include definite AF and probable AF (SVT likely to be AF depending on rate and other characteristics).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omega -3 fatty acids
Study Locations (1)
Massachusetts
- US, Italy and Argentina - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
What the finished NCT00970489 record still lists
NCT00970489 is an interventional study that assigns participants to a tested intervention. Its 1,516 participants enrollment target places it among the larger protocols in the corpus, below the 2,989-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00970489 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00970489 about?
NCT00970489 is a clinical study titled "Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation". This is a large multi-center study to examine whether peri-operative intake of n-3 polyunsaturated fatty acids (PUFA) will reduce the occurrence of post-operative atrial fibrillation or flutter (AF) in patients undergoing cardiac surgery (CS).
What is the current status of trial NCT00970489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,516 participants. The study started on 2010-08. Estimated completion is 2012-06.
What conditions does trial NCT00970489 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00970489?
The interventions under investigation include: Placebo (DRUG), Omega -3 fatty acids (DRUG).
Who is sponsoring clinical trial NCT00970489?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00970489 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00970489's enrollment target sits among peer trials
1,516 31st of 202 higher than 172 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia